Comparison of instruments for measuring the quality of life impairment syndrome in severe mental disorders

Q-LES-Q versus QLS and LQOLP
  • Michael S. Ritsner


In the present chapter, we compared the psychometric properties of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) with the Quality of Life Scale (QLS) and the Lancashire Quality of Life Profile (LQOLP) in the same patients with schizophrenia, schizoaffective, and mood disorders. These instruments were chosen since they are mental illness-related, and Q-LES-Q is a self-report evaluation scale, whereas QLS is observer-rated, and LQOLP has domains similar to Q-LES-Q, which enables a comparison of the instruments. The compared instruments proved to be mental health-related, but none were mental-disorder-specific. Despite the acceptable psychometric properties and the correlation of the general indices, similar domains proved to be instrument-specific and were not sufficiently compatible. These discrepancies should be considered when comparing evaluations from similar domains in these scales

Key words

Psychiatric patients Quality of life scales Reliability Validity Comparison 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321–326.PubMedGoogle Scholar
  2. 2.
    Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388–398.PubMedGoogle Scholar
  3. 3.
    Oliver J, Huxley P, Bridges K, Mohammed H. Quality of Life and Mental Health Service. London & New York: Routledge, 1996.Google Scholar
  4. 4.
    Van Nieuwenhuizen C, Schene AH, Boevink WA, Wolf JRLM. Measuring the quality of life of clients with severe mental illness: a review of instruments. Psychiatr Rehabil J 1997; 20:33–41.Google Scholar
  5. 5.
    Awad AG, Voruganti LN, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics. 1997; 11:32–47.PubMedGoogle Scholar
  6. 6.
    Bishop SL, Walling DP, Dott SG, Folkes CC, Bucy J. Refining quality of life: validating a multidimensional factor measure in the severe mentally ill. Qual Life Res 1999; 8:151–160.PubMedCrossRefGoogle Scholar
  7. 7.
    Hawthorne G, Richardson J. Measuring the value of program outcomes: a review of multiattribute utility measures. Expert Rev. Pharmacoeconomics Outcomes Res. 2001; 1: 215–228.CrossRefGoogle Scholar
  8. 8.
    Trauer T, Duckmanton RA, Chiu E. A study of the quality of life of the severely mentally ill. Int J Soc Psychiatry 1998; 44:79–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Lobana A, Mattoo SK, Basu D, et al. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr Scand 2001; 104:51–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Fitzgerald PB, Williams CL, Corteling N, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 2001; 103:387–392.PubMedCrossRefGoogle Scholar
  11. 11.
    Ruggeri M, Bisoffi G, Fontecedro L, et al. Subjective and objective dimensions of quality of life in psychiatric patients: a factor analytical approach: The South Verona Outcome Project 4. Br J Psychiatry 2001; 178:268–275.PubMedCrossRefGoogle Scholar
  12. 12.
    Lehman AF, Postrado LT, Rachuba LT. Convergent validation of quality of life assessments for persons with severe mental illnesses. Qual. Life Res. 1993: 2: 327–333.PubMedCrossRefGoogle Scholar
  13. 13.
    Oliver JP, Huxley PJ, Priebe S, Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol 1997; 32:76–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Ritsner M, Modai I, Endicott J, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000; 61:880–889.PubMedCrossRefGoogle Scholar
  15. 15.
    Ritsner M, Ponizovsky A, Endicott J, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12:31–38.PubMedCrossRefGoogle Scholar
  16. 16.
    Rossi A, Rucci P, Mauri M, Maina G, Pieraccini F, Pallanti S, Endicott J; (For the EQUIP group). Validity and reliability of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. Qual Life Res. 2005; 14(10):2323–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Ozer S, Ulusahin A, Batur S, et al. Outcome measures of interepisode bipolar patients in a Turkish sample. Soc Psychiatry Psychiatr Epidemiol. 2002; 37:31–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 1998; 48: 157–161.PubMedCrossRefGoogle Scholar
  19. 19.
    Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety. 2001;13:18–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Michalak EE, Tam EM, Manjunath CV, et al. Quality of life in patients with seasonal affective disorder: summer vs winter scores. Can J Psychiatry. 2005; 50:292–295.PubMedGoogle Scholar
  21. 21.
    Goracci A, Martinucci M, Scalcione U, et al. Quality of life and subthreshold affective symptoms. Qual Life Res. 2005; 14:905–909.PubMedCrossRefGoogle Scholar
  22. 22.
    Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000; 61:101–109.PubMedCrossRefGoogle Scholar
  23. 23.
    Ritsner M, Kurs R, Gibel A, et al. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry 2003; 64:308–315.PubMedCrossRefGoogle Scholar
  24. 24.
    Rapaport MH, Endicott J, Clary CM. Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry. 2002; 63: 59–65.PubMedGoogle Scholar
  25. 25.
    Ritsner M, Kurs R, Gibel A, et al. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005; 14:1693–1703.PubMedCrossRefGoogle Scholar
  26. 26.
    Katschnig, H. How useful is the concept of quality of life in psychiatry? Curr Opin Psychiatry 1997; 10: 337–345.CrossRefGoogle Scholar
  27. 27.
    Ritsner M, Kurs R. Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia. Expert Review and Pharmacoeconomic Outcomes Research 2002; 2: 89–98.Google Scholar
  28. 28.
    Ritsner M, Kurs R. Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders. Expert Review and Pharmacoeconomic Outcomes Research 2003; 3:189–199.CrossRefGoogle Scholar
  29. 29.
    Bilker, W.B., Brensinger, C., Kurtz, M.M., et al. Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology 2003; 28: 773–777.PubMedCrossRefGoogle Scholar
  30. 30.
    Ritsner M, Kurs R, Ratner Y, Gibel A. Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Psychiatry Res. 2005; 135:65–75.PubMedCrossRefGoogle Scholar
  31. 31.
    Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics. 1999;15: 469–480.Google Scholar
  32. 32.
    Kaneda Y, Ohmori T. Effects of quetiapine on gonadal axis hormones in male patients with schizophrenia: a preliminary, open study. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:875–878.PubMedCrossRefGoogle Scholar
  33. 33.
    Kaneda Y, Imakura A, Fujii A, Ohmori T. Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res. 2002;113:107–113.PubMedCrossRefGoogle Scholar
  34. 34.
    Cramer JA, Rosenheck R, Xu W, et al. Quality of Life in Schizophrenia: A Comparison of Instruments. Schizophr Bull 2000; 26: 659–666.PubMedGoogle Scholar
  35. 35.
    Ritsner, M., Perelroyzen, G., Kurs, R., et al. Quality of life outcomes in schizophrenia patients treated with atypical and typical antipsychotic agents: A naturalistic comparative study. International Clinical Psychopharmacology 2004; 24:582–591.CrossRefGoogle Scholar
  36. 36.
    Ritsner M, Perelroyzen G, Ilan H, Gibel A. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. 2004; 24:245–54.PubMedCrossRefGoogle Scholar
  37. 37.
    Ritsner MS, Gibel, A. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: a 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2006; 30:1442–1452.CrossRefGoogle Scholar
  38. 38.
    Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res 2000; 43:135–145.PubMedCrossRefGoogle Scholar
  39. 39.
    Gourevitch R, Abbadi S, Guelfi JD. Quality of life in schizophrenics with and without the deficit syndrome. Eur Psychiatry. 2004; 19:172–174.PubMedCrossRefGoogle Scholar
  40. 40.
    Lehman AF. (1995) Measuring quality of life in a reformed health system. Health Affairs 1995; 14: 90–101.CrossRefGoogle Scholar
  41. 41.
    Ritsner M, Modai I, Kurs R, et al. Subjective Quality of Life Measurements in Severe Mental Health Patients: Measuring Quality of Life of Psychiatric Patients: Comparison Two Questionnaires. Quality Life Research 2002; 11: 553–561.CrossRefGoogle Scholar
  42. 42.
    Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004; 18:877–893.PubMedCrossRefGoogle Scholar
  43. 43.
    Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004 (Suppl 2): 5–17; discussion 41–43.CrossRefGoogle Scholar
  44. 44.
    Voruganti L, Heslegrave R, Awad AG, Seeman MV. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998; 28:165–172.PubMedCrossRefGoogle Scholar
  45. 45.
    McKenna, S.P. Measuring quality of life in schizophrenia. Eur. Psychiatry 1997 (Suppl. 3), 267s–274s.CrossRefGoogle Scholar
  46. 46.
    Wilkinson, G., Hesdon, B., Wilde, D., et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br. J. Psychiatry 2000; 177: 42–46.PubMedCrossRefGoogle Scholar
  47. 47.
    Bernhard J, Lowy A, Mathys N, et al. Health related quality of life: a changing construct? Qual Life Res. 2004; 13:1187–1197.PubMedCrossRefGoogle Scholar

Copyright information

© springer 2007

Authors and Affiliations

  • Michael S. Ritsner
    • 1
  1. 1.Department of PsychiatryThe Rappaport Faculty of Medicine, Technion - Israel Institute of Technology and Acute Department Sha’ar Menashe Mental Health CenterIsrael

Personalised recommendations